DECLINE OF PHYSICAL PERFORMANCE IN PATIENTS RECEIVING RENAL REPLACEMENT THERAPY: FOCUS ON SARCOPENIA
https://doi.org/10.24884/1561-6274-2017-21-4-9-29
Abstract
The sarcopenia is an important cause of reduced physical performance in patients receiving renal replacement therapy. Discusses diagnostic criteria, mechanisms of development and methods of correction.
About the Authors
A. V. Smirnov
Research Institute of Nephrology;
Pavlov First St-Petersburg State Medical University
Russian Federation
Russian Federation
Prof., MD, PhD, DMedSci.
Research Institute of Nephrology, director.
First Pavlov St-Petersburg State Medical University; Department of propedeutic of internal diseases
197022, Russia, St-Petersburg, L. Tolstoy st., 17, build. 54, Phone: (812) 338-69- 01;
R. V. Golubev
First Pavlov St-Petersburg State Medical University
Russian Federation
Russian Federation
MD, PhD
First Pavlov St-Petersburg State Medical University,
Research Institute of Nephrology, Laboratory of Renal Insufficiency, head.
197022, Russia, St-Petersburg, L. Tolstoy st., 17, build. 54, Phone: (812) 338-69-14;
N. Yu. Korosteleva
First Pavlov St-Petersburg State Medical University
Russian Federation
Russian Federation
MD, PhD
First Pavlov St-Petersburg State Medical University;
Research Institute of Nephrology, Laboratory of Renal Insufficiency.
197022, Russia, St-Petersburg, L. Tolstoy st., 17, build. 54, Phone: (812) 338-69-14
A. Sh. Rumyantsev
Pavlov First Saint-Petersburg State Medical University;
Saint Petersburg State University
Russian Federation
Russian Federation
Prof., MD, PhD, DMedSci
Pavlov First Saint-Petersburg State Medical University, Department of propedeutic of internal diseases;
Saint Petersburg State University, Department of Faculty Therapy
Russia, 199106, Saint Petersburg, V.O., 21 line 8a., Phone: +7(812) 326-03-26
References
1. Rosenberg IH. Epidemiologic and methodologic problems in determining nutritional status of older persons. Am J Clin Nutr 1989; 50(5Suppl):1231–1235
2. Marcus RL, LaStayo PC, Ikizler TA et al. Low physical function in maintenance hemodialysis patients is independent of muscle mass and comorbidity. J Ren Nutr 2015; 25(4): 371-375. doi: 10.1053/j.jrn.2015.01.020
3. Correa-de-Araujo R, Hadley E. Skeletal muscle function deficite: a new terminology to embrace the evolving concepts of sarcopenia and age-related muscle dysfunction. J Gerontol A Biol Sci Med Sci 2014; 69(5): 591-594. doi: 10.1093/gerona/glt208
4. Cruz-Jentoft AJ, Baeyenns JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39(4): 412-423. doi: 10.1093/ageing/afq034
5. Evans WJ, Morley JE, Argiles J et al. Cachexia: a new definition. Clin Nutr 2008; 27(6): 793–799. doi: 10.1016/j.clnu.2008.06.013
6. Argiles JM, Campos N, Lopez-Pedrosa JM et al. Skeletal muscle regulates metabolism via interorgan crosstalk: roles in health and disease. JAMDA 2016; 17(9): 789-796. doi: 10.1016/j.jamda.2016.04.019
7. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56(3): M146–M156
8. Jeejeebhou KN. Malnutrition, fatigue, frailty, vulnerability, sarcopenia ahn cachexia: overlap of clinical features. Curr Opin Clin Nutr Metab Care 2012, 15(3):213–219. doi:10.1097/MCO.0b013e328352694f
9. Obi Y, Qader H, Kovesdy CP, Kalantar-Zadeh K. Latest consensus and update on protein energy-wasting in chronic kidney disease. Curr Opin Clin Nutr Metab Care 2015; 18(3): 254–262. doi:10.1097/MCO.0000000000000171
10. Serratrice G, Toga M, Roux H et al. Neuropathies, myopathies and neuromyopathies in chronic uremic patients. Presse Med 1967; 75(37): 1835-1838
11. Fahal IH. Uraemic sarcopenia: aetiology and implications. Nephrol Dial Transplant 2014; 29(9): 1655–1665 doi: 10.1093/ndt/gft070
12. Carrero JJ, Johansen KL, Lindholm B et al. Screening for muscle wasting and dysfunction in patients with chronic kidney disease. Kidney Int 2016; 90(1): 53-66. doi: 10.1016/j.kint.2016.02.025
13. Beaudart C, McCloskey E, Bruyere O et al. Sarcopenia in daily practice: assessment and management. BMC Geriatrics 2016; 16(1):170. doi:10.1186/s12877-016-0349-4
14. Dawson-Hughes B, Bishoff-Ferrari H. Considerations concerning the definition of sarcopenia. Osteoporos Int 2016; 27(11): 3139-3144. doi: 10.1007/s00198-016-3674-8
15. Correa-de-Araujo R, Harris-Love MO, Milikovic I et al. The need for standardized assessment of muscle quality in Skeletal Muscle Function Deficit and other aging-related muscle dysfunctions: a symposium report. Front Physiol 2017; 8: 87. doi: 10.3389/fphys.2017.00087
16. Stenvinkel P, Carrero JJ, von Walden F et al. Muscle wastingin end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies. Nephrol Dial Transplant 2016; 31(7): 1070–1077. doi: 10.1093/ndt/gfv122
17. Ren H, Gong D, Jia F et al. Sarcopenia in patients undergoing maintenance hemodialysis: incidence rate, risk factors and its effect on survival risk. Renal Failure 2016; 38(3) : 364-371. doi: 10.3109/0886022X.2015.1132173
18. Guralnik JM, Simonsick EM, Ferrucci L et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994; 49(2): M85-M94
19. Peterson MJ, Thompson DK, Pieper CF et al. A novel analytic technique to measure associations berween circulating biomarkers and physical performance across the adult life span. J Gerontol A Biol Sci Med Sci 2016; 71(2): 196-202. doi: 10.1093/gerona/glv007
20. Curcio F, Ferro G, Basile C et al. Biomarkers in sarcopenia: a multifactorial approach. Exp Gerontol 2016; 85: 1-8. doi: 10.1016/j.exger.2016.09.007
21. Kittiskulnam P, Chertow GM, Carrero JJ et al. Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis. Kidney Int 2017; [Epub ahead of print]. doi: 10.1016/j.kint.2017.01.024
22. Oksa H, Pasternack A, Pasanen M. Serum urea-creatinine ratio as a prognostic index in hemodialysis patients. Clin Nephrol 1987; 27(3):125-130
23. Tufan F, Yildiz A, Dogan I et al. Urea to creatinin ratio: a forgotten marker of poor nutritional state in patients undergoing hemodialysis treatment. Aging Male 2015; 18(1): 49-53. doi: 10.3109/13685538.2014.908281
24. Greenhall GHB, Davenport A. Screening for muscle loss in patients established on peritoneal dialysis using bioimpedance. Eur J Clin Nutr 2017; 71(1): 70-75. doi: 10.1038/ejcn.2016.202
25. Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2015; 6(4): 197-207. doi: 10.1002/jcsm.12034
26. Kooman JP, Broers NJ, Usvyat L et al. Out of control: accelerated aging in uremia. Nephrol Dial Transplant 2013; 28(1): 48-54. doi: 10.1093/ndt/gfs451
27. Hirai K, Ookawara S, Morishita Y. Sarcopenia and physical inactivity in patients with chronic kidney disease. Nephrourol Mon 2016; 8(3):e37443. doi: 10.5812/numonthly.37443
28. Kim JK, Choi SR, Choi MJ et al. Prevalence of and factors associated with sarcopenia in eldery patients with end-stage renal disease. Clin Nutr 2014; 33(1): 64-68. doi: 10.1016/j.clnu.2013.04.002
29. Fitschen PJ, Biruete A, Jeong J, Wilund KR. Efficacy of beta-hydroxy-betamethylbutyrate supplementation in maintenance hemodialysis patients. Hemodial Int 2016; doi: 10.1111/hdi.12440
30. Isoyama N, Qureshi AR, Avesani CM et al. Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. Clin J Am Soc Nephrol 2014; 9(10): 1720-1728. doi: 10.2215/CJN.10261013
31. Yamada S, Tsuruya K, Yoshida H et al. Factors associated with the serum myostatin level in patients undergoing peritoneal dialysis: potential effects of skeletal muscle mass and vitamin D receptor activator use. Calcif Tissue Int 2016; 99(1): 13-22. doi: 10.1007/s00223-016-0118-6
32. Jamal SA, Leiter RE, Jassal V et al. Impaired muscle strength is associated with fractures in hemodialysis patients. Osteoporos Int 2006; 17(9): 1390–1397. doi:10.1007/s00198-006-0133-y
33. Rhee CM, Kalantar-Zadeh K. Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients? J Cachexia Sarcopenia Muscle 2014; 5(3): 177-180. doi: 10.1007/s13539-014-0160-z
34. Avin KG, Moorthi RN. Bone is not alone: the effects of skeletal muscle dysfunction in chronic kidney disease. Curr Osteoporos Rep 2015; 13(3): 173-179. doi: 10.1007/s11914-015-0261-4
35. Shefer G, Van de Mark DP, Richardson JB, Yablonka-Reuveni Z. Satellite-cell pool size does matter: defining the myogenic potency of aging skeletal muscle. Dev Biol 2006; 294(1): 50–66. doi:10.1016/j.ydbio.2006.02.022
36. Motohashi N, Asakura A. Muscle satellite cell heterogeneity and self-renewal. Front Cell Dev Biol 2014; 2:1. doi: 10.3389/fcell.2014.00001
37. Wang XH, Du J, Klein JD et al. Exercise ameliorates chronic kidney disease-induced defects in muscle protein metabolism and progenitor cell function. Kidney Int 2009; 76(7): 751-759. doi: 10.1038/ki.2009.260
38. Rubattu S, Mennuni S, Testa M et al. Pathogenesis of chronic cardiorenal syndrome: is there a role for oxidative stress? Int J Mol Sci 2013; 14(11): 23011-23032. doi: 10.3390/ijms141123011
39. Burks TN, Andres-Mateos E, Marx R et al. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med 2011; 3(82): 82ra37. doi: 10.1126/scitranslmed.3002227
40. Reginster JY, Beaudart C, Buckinx F, Bruyere O. Osteoporosis and sarcopenia: two diseases or one? Curr Opin Clin Nutr Metab Care 2016; 19(1): 31-36. doi: 10.1097/MCO.0000000000000230
41. Girgis CM. Therapies for musculoskeletal disease: can we treat two birds with one stone? Curr Osteoporos Rep 2014; 12(2): 142-153. doi: 10.1007/s11914-014-0204-5
42. Pedersen BK, Steenberg A, Fisher C et al. Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil 2003; 24(2-3): 113-119
43. Tagliaferri C, Wittrant Y, Davicco M-J et al. Muscle and bone, two interconnected tissues. Ageing Res Rev 2015; 21: 55-70. doi: 10.1016/j.arr.2015.03.002
44. Sjöblom S, Suuronen J, Rikkonen T et al. Relationship between postmenopausal osteoporosis and the components of clinical sarcopenia. Maturitas 2013; 75(2): 175-180. doi: 10.1016/j.maturitas.2013.03.016
45. Vogt BP, Borges MC, Goes CR, Caramori JC. Handgrip strength is an independent predictor of all-cause mortality in maintenance dialysis patients. Clin Nutr 2016; 35(6): 1429-1433. doi: 10.1016/j.clnu.2016.03.020
46. Bischoff HA, Borchers M, Gudat F. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 2001; 33(1):19-24
47. Girgis CM, Baldock PA, Downes M. Vitamin D, muscle and bone: integrating effects in development, aging and injury. Mol Cell Endocrinol 2015; 410: 3-10. doi: 10.1016/j.mce.2015.03.020
48. Kim J, Lee Y, Kye S et al. Association of serum vitamin D with osteosarcopenic obesity: Korea National Health and Nutrition Survey 2008-2010. J Cachexia Sarcopenia Muscle 2016; [Epub ahead of print]. doi: 10.1002/jcsm.12154
49. Garcia LA, King KK, Ferrini MG et al. 1,25(OH)2 vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology 2011; 152(8): 2976-2986. doi: 10.1210/en.2011-0159
50. Buehring B, Binkley N. Myostatin – the holy grail for muscle, bone and fat? Curr Osteoporos Res 2013; 11(4): 407-414. doi: 10.1007/s11914-013-0160-5
51. Briffa JF, McAinch AJ, Poronnik P, Hrychiw H. Adipokines is a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol 2013; 305(12): F1629-F1636. doi: 10/1152/ajprenal.00263.2013
52. Nashar K, Egan BM. Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes Metab Syndr Obes 2014; 7:421-435. doi: 10.2147/DMSO.S45183
53. Lee D, Shook RP, Drenowatz C, Blair SN. Physical activity and sarcopenic obesity: definition, assessment, prevalence and mechanism. Future Sci OA 2016; 2(3): FSO127. doi: 10.4155/fsoa-2016-0028
54. Jackman RW, Kandarian SC. The molecular basis of skeletal muscle atrophy. Am J Physiol Cell Physiol 2004; 287(4): C834-C843. doi: 10.1152/ajpcell.00579.2003
55. Enoki Y, Watanabe H, Arake R et al. Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stressmediated expression of myostatin and atrogin-1. Sci Rep 2016; 6:32084. doi: 10.1038/srep32084
56. Kaizu Y, Ohkawa S, Odamaki M et al. Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. Am J Kidney Dis 2003; 42(2): 295-302
57. Mitch WE, Price SR. Mechanisms activated by kidney disease and the loss of muscle mass. Am J Kidney Dis 2001; 38(6): 1337-1342. doi: 10.1053/ajkd.2001.29249
58. Du J, Wang H, Miereles C et al. Activation of caspase-3 is an initial step triggered accelerated muscle proteolysis in catabolic conditions. J Clin Invest 2004; 113(1):115-123. doi: 10.1172/JCI200418330
59. Boivin MA, Battah SI, Dominic EA et al. Activation of caspase-3 in the skeletal muscle during hemodialysis. Eur J Clin Invest 2010; 40(10): 903-910. doi: 10.1111/j.1365-2362.2010.02347.x
60. Sallée M, Dou L, Cerini C et al. The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease. Toxins 2014; 6(3): 934-949. doi:10.3390/toxins6030934
61. Ikizler TA, Pupim LB, Brouillette JR et al. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab 2002; 282(1): E107–E116
62. Nitta K, Tsuchiya K. Recent advances in the pathophysiology and management of protein-energy wasting in chronic kidney disease. Ren Replacement Ther 2016; 2:4. doi: 10.1186/s41100-016-0015-5
63. Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron 1992; 61(4): 377-382
64. Spoto B, Pisano A, Zoccalli C. Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol 2016; 311(6): F1087-F1108. doi: 10.1152/ajprenal.00340.2016
65. Siew ED, Pupim LB, Majchrzak KM et al. Insulin resistance is associated with skeletal muscle protein breakdown in nondiabetic chronic hemodialysis patients. Kidney Int 2007; 71(2): 146-52. doi: 10.1038/sj.ki.5001984
66. Rabkin R, Sun DF, Chen Y et al. Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling. Pediatr Nephrol 2005; 20(3): 313-318. doi: 10.1007/s00467-004-1713-8
67. Pupim LB, Flakoll PJ, Majchrzak KM et al. Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. Kidney Int 2005; 68(4): 1857-65. doi: 10.1111/j.1523-1755.2005.00605.x
68. Wang XH, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 2006; 147(9): 4160-4168. doi: 10.1210/en.2006-0251
69. Chien YH, Han DS, Hwu WL et al. Myostatin and insulinlike growth factor 1: potential therapeutic biomarkers for pompe disease. PloS One 2013; 8(8): e71900. doi: 10.1371/journal. pone.0071900
70. Amthor H, Macharia R, Navarrete R et al. Lack of myostatin results in excessive muscle growth but impaired force generation. Proc Natl Acad Sci USA 2007; 104(6): 1835-1840. doi: 10.1073/pnas.0604893104
71. Breitbart A, Auger-Messier M, Molkentin JD, Heineke J. Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am J Physiol Heart Circ Physiol 2011; 300(6): H1973-H1982. doi: 10.1152/ajpheart.00200.2011
72. Zhang L, Rajan V, Lin E et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 2011; 25(5): 1653-1663. doi: 10.1096/fj.10-176917
73. Yano S, Nagai A, Isomura M et al. Relationship between blood myostatin levels and kidney function: Shimane CoHRE study. PloS One 2015; 10(10): e0141035. doi: 10/1371/journal. pone.0141035
74. Han DS, Chen YM, Lin SY et al. Serum miostatin levels and grip strength in normal subjects and patients on maintenance hemodialysis. Clin Endocrin 2011; 75(6): 857-863. doi: 10.1111/1365-2265.2011.04120.x
75. Lee SJ. Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One 2007; 2(8): e789. doi: 10.1371/journal.pone.0000789
76. Wen MS, Wang CY, Lin SL et al. Decrease in irisin in patients with chronic kidney disease. PLoS One 2013; 8(5): e64025. doi: 10.1371/journal.pone.0064025
77. Chang JS, Kim TH, Nguyen TT et al. Circulating irisin levels as a predictive biomarker for sarcopenia: a cross-sectional community-based study. Geriatr Gerontol Int 2017; [Epub ahead of print]. doi: 10.1111/ggi.13030.
78. Ebert T, Focke D, Petroff D et al. Serum levels of the myokine irisin in relation to metabolic and renal function. Eur J Endocrinol 2014; 170(4): 501-506. doi: 10.1530/EJE-13-1053
79. Lee MJ, Lee SA, Nam BY et al. Irisin, a novel myokine is an independent predictor for sarcopenia and carotid atherosclerosis in dialysis patients. Atherosclerosis 2015; 242(2): 476-482. doi: 10.1016/j.atherosclerosis.2015.08.002
80. Carrero JJ, Qureshi AR, Nakashima A et al. Prevalence and clinical implications of testosterone deficiency in men with endstage renal disease. Nephrol Dial Transplant 2011; 26(1):184-190. doi: 10.1093/ndt/gfq397
81. Granata S, Zaza G, Simone S et al. Mytochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 2009; 10: 388. doi: 10.1186/1471-2164-10-388
82. Rai DS, Boivin MA, Dominic EA et al. Haemodialysis induces mitochondrial dysfunction and apoptosis. Eur J Clin Invest 2007; 37(12): 971-977. doi: 10.1111/j.1365-2362.2007.01886.x
83. Adey D, Kumar R, McCarthy JT et al. Reduced synthesis of muscle proteins in chronic renal failure. Am J Physiol Endocrinol Metab 2000; 278(2): E219-E225
84. Gamboa JL, Billings FT, Bojanowski MT et al. Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiol Rep 2016; 4(9): e12780. doi: 10.14814/phy2.12780
85. Gonzalez-Freire M, de Cabo R, Studenski SA, Ferrucci L. The neuromuscular junction: aging at the crossroad between nerves and muscle. Front Aging Neurosci 2014; 6: 208. doi: 10.3389/fnagi.2014.00208
86. Stout JR, Fragala MS, Hoffman JR et al. C-terminal agrin fragment is inversely related to neuromuscular fatigue in older man. Muscle Nerve 2015; 51(1): 132-133. doi: 10.1002/mus.24443
87. Sanguinetti R, Puddu A, Mach F et al. Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm 2014: 975872. doi: 10.1155/2014/975872.
88. Tanaka K, Kanazawa I, Yamaguchi T et al. Active vitamin D possesses beneficial effect on the interaction between muscle and bone. Biochem Biophys Res Commun 2014; 450(1): 482-487. doi: 10.1016/j.bbrc.2014.05.145
89. Brunjes DL, Kennel PJ, Christian Schulze P. Exercise capacity, physical activity, and morbidity. Heart Fail Rev 2017; [Epub ahead of print]. doi: 10.1007/s10741-016-9592-1
90. Begini P, Gigante E, Antonelli G et al. Sarcopenia predicts reduced survival in patients with hepatocellular carcinoma at first diagnosis. Ann Hepatol 2017; 16(1): 107-114. doi: 10.5604/16652681.1226821
91. Harada K, Suzuki S, Ishii H et al. Impact of skeletal muscle mass on long-term adverse cardiovascular outcomes in patients with chronic kidney disease. Am J Cardiol 2017; [Epub ahead of print]. doi: 10.1016/j.amjcard.2017.01.003
92. Crawford J. Clinical results in cachexia therapeutics. Curr Opin Clin Nutr Metab Care 2016; 19(3): 199-204. doi: 10.1097/MCO.0000000000000274
93. O’Brien FJ, Fong KD, Sirich TL, Meyer TW. More dialysis has not proven much better. Semin Dial 2016; 29(6): 481-490. doi: 10.1111/sdi.12533
94. Chertow GM, Levin NW, Beck GJ et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363(24): 2287-300. doi: 10.1056/NEJMoa1001593 96. Смирнов АВ, Нестерова ОБ, Голубев РВ и др. Кардиопротективные эффекты сукцинатсодержащего диализирующего раствора. Нефрология 2012; 16(2): 69-78 [Smirnov AV, Nesterova OB, Golubev RV i dr. Kardioprotektivnye effekty suktcinatsoderzhashchego dializiruiushchego rastvora. Nephrology 2012; 16(2): 69-78]
95. Смирнов АВ, Нестерова ОБ, Суглобова ЕД и др. Клинико-лабораторная оценка эффективности лечения больных с терминальной стадией почечной недостаточности с использованием хронического гемодиализа и ацидосукцината. Тер Арх 2013; 85(1): 69-75 [Smirnov AV, Nesterova OB, Suglobova ED i dr. Cliniko-laboratornaia ocenka effektivnosti lecheniia bolnyh s terminalnoi stadiei pochechnoi nedostatochnosti s ispolzovaniem khronicheskogo gemodializa i atcidosuktcinata. Ter Arkh 2013; 85(1): 69-75]
96. Смирнов АВ, Васильева ИА, Нестерова ОБ и др. Качество жизни и когнитивные функции у пациентов с терминальной стадией почечной недостаточности, получающих гемодиализ с использованием сукцинатсодержащего диализирующего раствора. Тер Арх 2014; 86(6): 11-17 [Smirnov AV, Vasilyeva IA, Nesterova OB i dr. Kachestvo zhizni i kognitivnye funktcii u patcientov s terminalnoi stadiei pochechnoi nedostatochnosti, poluchaiushchikh gemodializ s ispol`zovaniem suktcinatsoderzhashchego dializiruiushchego rastvora. Ter Arkh 2014; 86(6): 11-17]
97. Смирнов АВ, Голубев РВ, Васильев АН и др. Гемодинамические эффекты содержащего сукцинат диализирующего раствора. Тер Арх 2015; 87(6): 56-61. doi: 10.17116/ terarkh201587656-61 [Smirnov AV, Golubev RV, Vasilev AN i dr. Gemodinamicheskie e`ffekty soderzhashchego suktcinat dializiruiushchego rastvora. Ter Arkh 2015; 87(6): 56-61. doi: 10.17116/terarkh201587656-61]
98. Wallimann T, Riek U, Möddel M. Intradialytic creatin supplementation: a scientific rationale for improving the health and quality of life of dialysis patients. Med Hypotheses 2017; 99: 1-14. doi: 10.1016/j.mehy.2016.12.002
99. Wallimann T, Tokarska-Schlattner M, Schlattner U. The creatine kinase system and pleiotropic effects of creatine. Amino Acids 2011; 40(5): 1271-1296. doi: 10.1007/s00726-011-0877-3
100. Cooper R, Naclerio F, Allgrove J, Jimenez A. Creatine
101. supplementation with specific view to exercise/sports performance: an update. J Int Soc Sports Nutr 2012; 9(1): 33. doi: 10.1186/1550-2783-9-33
102. Taes YE, Delanghe JR, De Bacquer D et al. Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients. Kidney Int 2004; 66(6): 2422-2428. doi: 10.1111/j.1523-1755.2004.66019.x
103. Lamon S, Zacharewicz E, Arentson-Lantz E et al. Erythropoietin does not enhance skeletal muscle protein synthesis following exercise in young and older adults. Front Physiol 2016; 7: 292. doi: 10.3389/fphys.2016.00292
104. de Cavanagh EM, Piotrkowski B, Basso N et al. Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J 2003; 17(9): 1096-1098. doi: 10.1096/fj.02-0063fje
105. Maggio M, Ceda GP, Lauretani F et al. Relation of angiotensin converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects. Am J Cardiol 2006; 97(10): 1525-1529. doi: 10.1016/j.amjcard.2005.11.089
106. Onder G, Penninx BWJH, Balkrishnan et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002; 359(9310): 926-930
107. KDIGO CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD). Kidney Int Suppl 2009; 113: S1-S130. doi: 10.1038/ki.2009.188
108. Collamati A, Marzetti E, Calvani R et al. Sarcopenia in heart failure: mechanisms and therapeutic strategies. J Geriatr Cardiol 2016; 13(7): 615-624. doi: 10.11909/j.issn.1671-5411.2016.07.004
109. Taskapan H, Baysal O, Karahan D et al. Vitamin D and muscle strength, functional ability and balance in peritoneal dialysis patients with vitamin D deficiency. Clin Nephrol 2011; 76(2): 110-116
110. Johansen KL, Painter PL, Sakkas GK et al. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol 2006; 17(8): 2307-2314. doi: 10.1681/ASN.2006010034
111. Boccanfuso JA, Hutton M, McAllister B. The effects of megestrol acetate on nutritional parameters in a dialysis population. J Ren Nutr 2000; 10(1): 36-43. doi: 10.1053/JREN01000036
112. Hansen TB, Gram J, Jensen PB et al. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study. Clin Nephrol 2000; 53(2): 99-107
113. Feldt-Rasmussen B, Lange M, Sulowicz W et al. Growth hormone treatment during hemodialysis in a randomised trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 2007; 18(7): 2161-2171. doi: 10.1681/ASN.2006111207
114. Moledina DG, Wilson FP. Pharmacologic treatment of common symptoms in dialysis patients: a narrative review. Semin Dial 2015; 28(4): 377-383. doi: 10.1111/sdi.12378
115. Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options. Gerontology 2014; 60(4): 294-305. doi: 10.1159/000356760
116. Haruta I, Fuku Y, Kinoshita K et al. One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient. J Cachexia Sarcopenia Muscle 2015; 6(3): 237-241. doi: 10.1002/jcsm.12028
117. Ashby DR, Ford HE, Winne KJ et al. Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int 2009; 76(2): 199-206. doi: 10.1038/ki.2009.114
118. Zhang YM, Zhuo L, Hu J et al. Clinical significance of different carnitine levels for improving the prognosis of patients undergoing hemodialysis. Ren Fail 2016; 38(10): 1654-1658. doi: 10.1080/0886022X.2016.1229967
119. Babcock TA, Helton WS, Espat NJ. Eicosapentaenoic acid (EPA): an anti-inflammatory ω-3 fat with potential clinical application. Nutrition 2000; 16(11-12): 1116-1118
120. Magee P, Pearson S, Allen J. The omega-3 fatty acid, eicosapentaenoic acid (EPA), prevents the damaging effects of tumor necrosis factor (TNF)-alfa during murine skeletal muscle cell differentiation. Lipids Health Dis 2008; 7: 24. doi: 10.1186/1476-511X-7-24
121. Smith GI, Atherton P, Reeds DN et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr 2011; 93(2): 402-412. doi: 10.3945/ajcn.110.005611
122. Wang ZH, Hsu CC, Huang CN, Yin MC. Antiglycative effects of oleanoic acid and ursolic acid in kidney of diabetic mice. Eur J Pharm 2010; 628(1-3): 255-260. doi: 10.1016/j.ejphar.2009.11.019
123. Kunkel SD, Suneja M, Ebert SM et al. mPNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab 2011; 13(6): 627-638. doi: 10.1016/j.cmet.2011.03.020
124. Sakuma K, Yamaguchi A. Novel intriguing strategies attenuating to sarcopenia. J Aging Res 2012; doi: 10.1155/2012/251217
125. Attie KM, Borgstein NG, Yang Y et al. A single ascendingdose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve 2013; 47(3): 416-423. doi: 10.1002/mus.23539
126. Krivickas LS, Walsh R, Amato AA. Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029. Muscle Nerve 2009; 39(1): 3-9. doi: 10.1002/mus.21200
127. Wissing ER, Millay DP, Vuagniaux G, Molkentin JD. Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice. Neuromuscul Disord 2010; 20(11): 753-760. doi: 10.1016/j.nmd.2010.06.016
128. Tseng YC, Kulp SK, Lai IL et al. Preclinical investigation of the novel histone deacetylase inhibitor AR-42 in the treatment of cancer-induced cachexia. J Natl Cancer Inst 2015; 107(12): djv274. doi: 10.1093/jnci/djv274
129. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease state. J Am Soc Nephrol 2006; 17(7): 1807-1819. doi: 10.1681/ASN.2006010083
130. Yu SCY, Khow KSF, Jadczak AD, Visvanathan R. Clinical screening tools for sarcopenia and its management. Curr Gerontol Geriart Res 2016; doi: 10.1155/2016/5978523
131. Franch HA. Nutrition and muscle catabolism in maintenance hemodialysis: does feeding make muscle cells selective self-eaters? J Ren Nutr 2009; 19(1): 86-90. doi: 10.1053/j.jrn.2008.10.009
132. Beaudart C, Dawson A, Shaw SC et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int 2017; [Epub ahead of print]. doi: 10.1007/s00198-017-3980-9
133. Kouidi E, Albani M, Natsis K et al. The effects of axercise training on muscle atrophy in haemodialysis patients. Nephrol Dial Transplant 1998; 13(3): 685-699
134. Baskin KK, Winders BR, Olson EN. Muscle as a «Mediator» of systemic metabolism. Cell Metab 2015; 21(2): 237-248. doi: 10.1016./j.cmet.2014.12.021
135. Manfredini F, Mallamaci F, D’Arrigo G et al. Exercise in patients on dialysis: a multicenter, randomized clinical trial. J Am Soc Nephrol 2016; [Epub ahead of print]. doi: 10.1681/ASN.2016030378
136. Konstantinidou E, Koukouvou G, Kouidi E et al. Exercise training in patient with end-stage renal disease on hemodialysis: comparison of three rehabilitation programs. J Rehabil Med 2002; 34(1): 40-45
137. Chen C-T, Lin S-H, Chen J-S, Hsu Y-J. Muscle wasting in hemodialysis patients: new therapeutic strategies for resolving an old problem. Sci World J 2013:643954; doi: 10.1155/2013/643954
138. Johansen KL, Painter P. Exercise in individuals with CKD. Am J Kidney Dis 2012; 59(1): 126-134. doi: 10.1053/j.ajkd.2011.10.008
139. Kopple JD, Wang H, Casaburi R et al. Exercise in maintenance hemodialysis patients induces transcriptional changes in genes favoring anabolic muscle. J Am Soc Nephrol 2007; 18(11): 2975-2986. doi: 10.1681/ASN.2006070794
140. Kirkman DL, Mullins P, Junglee NA et al. Anabolic exercise in hemodialysis patients: a randomized controlled pilot study. J Cachexia Sarcopenia Muscle 2014; 5(3): 199-207. doi: 10.1007/s13539-014-0140-3
141. Cheema B, Abas H, Smith B et al. Progressive exercise for anabolism in kidney disease (PEAK): a randomized, controlled trial of resistance training during hemodialysis. J Am Soc Nephrol 2007; 18(5): 1594-1601. doi: 10.1681/ASN.2006121329
142. Dong J, Sundell MB, Pupim LB et al. The effect of resistance exercise to augment long-term benefits of intradialytic oral nutritional supplementation in chronic hemodialysis patients. J Ren Nutr 2011; 21(2): 149-159. doi: 10.1053/j.jrn.2010.03.004
Review
For citations:
Smirnov A.V., Golubev R.V., Korosteleva N.Yu., Rumyantsev A.Sh. DECLINE OF PHYSICAL PERFORMANCE IN PATIENTS RECEIVING RENAL REPLACEMENT THERAPY: FOCUS ON SARCOPENIA. Nephrology (Saint-Petersburg). 2017;21(4):9-29. (In Russ.) https://doi.org/10.24884/1561-6274-2017-21-4-9-29
Views:
4255
Email this article 